M&A Deal Summary

Ropack Acquires Forest Laboratories - Pharmaceutical Facilities

On December 8, 2015, Ropack acquired packaging company Forest Laboratories - Pharmaceutical Facilities from Forest Laboratories

Acquisition Highlights
  • This is Ropack’s 1st transaction in the Packaging sector.
  • This is Ropack’s 1st transaction in the United States.
  • This is Ropack’s 1st transaction in New York.

M&A Deal Summary

Date 2015-12-08
Target Forest Laboratories - Pharmaceutical Facilities
Sector Packaging
Buyer(s) Ropack
Sellers(s) Forest Laboratories
Deal Type Divestiture

Target

Forest Laboratories - Pharmaceutical Facilities

Long Island, New York, United States
Forest Laboratories - Pharmaceutical Facilities is a provider of oral dosage packaging and distribution services.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ropack

Montreal, Quebec, Canada

Category Company
Founded 1976
Sector Packaging
DESCRIPTION

Ropack, Inc. is a provider of contract manufacturing and packaging services for the pharmaceutical and nutraceutical industries.


DEAL STATS #
Overall 1 of 1
Sector (Packaging) 1 of 1
Type (Divestiture) 1 of 1
State (New York) 1 of 1
Country (United States) 1 of 1
Year (2015) 1 of 1

Seller(S) 1

SELLER

Forest Laboratories

New York, New York, United States

Category Company
Founded 1956
Sector Medical Products
Employees5,800
Revenue 3.1B USD (2013)
DESCRIPTION

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe.


DEAL STATS #
Overall 1 of 1
Sector (Packaging) 1 of 1
Type (Divestiture) 1 of 1
State (New York) 1 of 1
Country (United States) 1 of 1
Year (2015) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-07-02 Furiex Pharmaceuticals

Morrisville, North Carolina, United States

Furiex Pharmaceuticals, Inc. is a drug development company focusing on treatment for gastroenterology disorders. Furiex Pharmaceuticals forms collaborations with innovators from both the biotechnology and pharmaceutical industry.

Buy $1.1B